Need help? +44 (0) 7457 418426

MEDICINE DETAILS

Inqovi

Active ingredient: Decitabine AND Cedazuridine

Neutral reference profile for an independent medicine-access consultancy enquiry about Inqovi (Decitabine AND Cedazuridine). No medicine is offered for sale.

NEXT STEP

Choose the strength and pack

No ready-made options were found for this medicine. You can type the details in the form.

Continue to the form

✓ If you are unsure, choose “I do not know”.

These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.

ABOUT THIS MEDICINE

What is Inqovi used for?

Inqovi (decitabine and cedazuridine) is a medication used for the treatment of adults with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

It is available in vial form, each containing 35 mg decitabine and 100 mg cedazuridine.

This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.

RECORDED PRODUCT PROFILE

Inqovi identity, dosage form and pack information.

The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.

Brand recordInqovi
Active ingredientDecitabine AND Cedazuridine
Dosage formCheck the pack record
Recorded options0
Directory areaOncology

Recorded strength and pack options

Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.

No ready-made option can be shown.

Do not guess a missing strength or pack; use the details on the prescription and medicine box.

OFFICIAL SOURCES

Check the Inqovi record at an official source.

Search for “Inqovi” or “Decitabine AND Cedazuridine”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.

SERVICE BOUNDARY

Information checking and independent enquiry support for Inqovi.

OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.

Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.

CLEAR ANSWERS

Frequently asked questions about Inqovi

01What is Inqovi?

This directory record associates the brand name Inqovi with the active ingredient Decitabine AND Cedazuridine. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.

02Which Inqovi strengths and packs are recorded?

No ready-made strength and pack option can currently be shown from the catalogue record. Do not guess missing details; use the prescription and medicine box.

03Who manufactures Inqovi?

No organisation name can currently be shown confidently from the catalogue record. Verify the manufacturer or marketing-authorisation holder on the pack leaflet and official regulatory record.

04Do the listed options confirm stock or access?

No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.

05What affects a possible estimated medicine cost for Inqovi?

A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Inqovi, payment request, stock guarantee or binding offer.

06Can I buy Inqovi from this website?

No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.